These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 24650055

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Targeted cancer therapy: from bench to bedside to patient.
    Gellad WF.
    J Clin Oncol; 2014 Feb 01; 32(4):268-70. PubMed ID: 24366939
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
    Taylor MJ, Scuffham PA.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr 01; 9(2):117-21. PubMed ID: 19402798
    [Abstract] [Full Text] [Related]

  • 7. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
    Conti RM, Padula WV, Larson RA.
    Ann Hematol; 2015 Apr 01; 94 Suppl 2(0 2):S249-57. PubMed ID: 25814091
    [Abstract] [Full Text] [Related]

  • 8. Imatinib for chronic myeloid leukaemia: a NICE mess.
    O'Brien SG.
    Lancet; 2001 Dec 01; 358(9296):1902-3. PubMed ID: 11741654
    [No Abstract] [Full Text] [Related]

  • 9. Perspective: combined forces.
    Sawyers CL.
    Nature; 2013 Jun 27; 498(7455):S7. PubMed ID: 23803949
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
    Romero M, Chávez D, De Los Ríos M, Alvis-Guzmán N.
    Biomedica; 2014 Jun 27; 34(1):48-59. PubMed ID: 24968906
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
    Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL.
    J Clin Oncol; 2014 Feb 01; 32(4):306-11. PubMed ID: 24366936
    [Abstract] [Full Text] [Related]

  • 17. Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country.
    Iqbal J, Ali Z, Khan AU, Aziz Z.
    Leuk Lymphoma; 2014 Sep 01; 55(9):2109-13. PubMed ID: 24237577
    [Abstract] [Full Text] [Related]

  • 18. Drug developers unveil strategies aimed at imatinib-resistant CML.
    Goozner M.
    J Natl Cancer Inst; 2010 May 05; 102(9):593-5. PubMed ID: 20421566
    [No Abstract] [Full Text] [Related]

  • 19. New directions in the treatment of patients with chronic myeloid leukemia: introduction.
    Baccarani M.
    Semin Hematol; 2009 Apr 05; 46(2 Suppl 3):S1-4. PubMed ID: 19621542
    [No Abstract] [Full Text] [Related]

  • 20. [Chronic myeloid leukemia 2008].
    Cervantes F.
    Med Clin (Barc); 2008 Nov 15; 131(17):658-9. PubMed ID: 19087793
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.